CDK2 and mTOR are direct molecular targets of isoangustone A in the suppression of human prostate cancer cell growth

Toxicology and Applied Pharmacology

Volumn 272, Issue 1, 2013, Pages 12-20

  Lee, Eunjung ^a   Son, Joe Eun ^a   Byun, Sanguine ^a   Lee, Seung Joon ^a   Kim, Yeong A ^a   Liu, Kangdong ^b   Kim, Jiyoung ^a   Lim, Soon Sung ^c   Park, Jung Han Yoon ^c   Dong, Zigang ^b   Lee, Ki Won ^a,d   Lee, Hyong Joo ^a,d  

^a Seoul National University   (South Korea)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Hallym University   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

CDK2; Licorice; MTOR; P27kip1; Prostate cancer

Indexed keywords

CYCLIN DEPENDENT KINASE 2; GLYCYRRHIZA EXTRACT; ISOANGUSTONE A; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P27; THREONINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CANCER SIZE; CONTROLLED STUDY; DRUG POTENCY; ENZYME ACTIVATION; ENZYME ACTIVITY; G1 PHASE CELL CYCLE CHECKPOINT; GLYCYRRHIZA; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; S PHASE CELL CYCLE CHECKPOINT; TUMOR XENOGRAFT;

CDK2; LICORICE; MTOR; P27(KIP1); PROSTATE CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P27; ENZYME ACTIVATION; FLUORESCENT ANTIBODY TECHNIQUE; GLYCYRRHIZIC ACID; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; INDICATORS AND REAGENTS; ISOFLAVONES; MALE; MICE; MICE, INBRED BALB C; PHOSPHORYLATION; PROSTATIC NEOPLASMS; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84882737116     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.04.030     Document Type: Article

References (49)

1. Asl M.N., Hosseinzadeh H. Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. Phytother. Res. 2008, 22:709-724.
2. Bertram J., Peacock J.W., Fazli L., Mui A.L., Chung S.W., Cox M.E., Monia B., Gleave M.E., Ong C.J. Loss of PTEN is associated with progression to androgen independence. Prostate 2006, 66:895-902.
3. Blain S.W., Scher H.I., Cordon-Cardo C., Koff A. p27 as a target for cancer therapeutics. Cancer Cell 2003, 3:111-115.
4. Bray F., Lortet-Tieulent J., Ferlay J., Forman D., Auvinen A. Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur. J. Cancer 2010, 46:3040-3052.
5. Byun S., Lee K.W., Jung S.K., Lee E.J., Hwang M.K., Lim S.H., Bode A.M., Lee H.J., Dong Z. Luteolin inhibits protein kinase C(epsilon) and c-Src activities and UVB-induced skin cancer. Cancer Res. 2010, 70:2415-2423.
6. Cairns P., Okami K., Halachmi S., Halachmi N., Esteller M., Herman J.G., Jen J., Isaacs W.B., Bova G.S., Sidransky D. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res. 1997, 57:4997-5000.
7. Cappellini A., Tabellini G., Zweyer M., Bortul R., Tazzari P.L., Billi A.M., Fala F., Cocco L., Martelli A.M. The phosphoinositide 3-kinase/Akt pathway regulates cell cycle progression of HL60 human leukemia cells through cytoplasmic relocalization of the cyclin-dependent kinase inhibitor p27(Kip1) and control of cyclin D1 expression. Leukemia 2003, 17:2157-2167.
8. Chapman M.E., Hu L., Plato C.F., Kohan D.E. Bioimpedance spectroscopy for the estimation of body fluid volumes in mice. Am. J. Physiol. Renal Physiol. 2010, 299:F280-F283.
9. Cheng C.J., Chen Y.H., Chau T., Lin S.H. A hidden cause of hypokalemic paralysis in a patient with prostate cancer. Support. Care Cancer 2004, 12:810-812.
10. Cherng J.M., Tsai K.D., Yu Y.W., Lin J.C. Molecular mechanisms underlying chemopreventive activities of glycyrrhizic acid against UVB-radiation-induced carcinogenesis in SKH-1 hairless mouse epidermis. Radiat. Res. 2011, 176:177-186.
11. Chu I., Sun J., Arnaout A., Kahn H., Hanna W., Narod S., Sun P., Tan C.K., Hengst L., Slingerland J. p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell 2007, 128:281-294.
12. Chu I.M., Hengst L., Slingerland J.M. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat. Rev. Cancer 2008, 8:253-267.
13. Di Cristofano A., De Acetis M., Koff A., Cordon-Cardo C., Pandolfi P.P. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat. Genet. 2001, 27:222-224.
14. DiPaola R.S., Zhang H., Lambert G.H., Meeker R., Licitra E., Rafi M.M., Zhu B.T., Spaulding H., Goodin S., Toledano M.B., Hait W.N., Gallo M.A. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N. Engl. J. Med. 1998, 339:785-791.
15. Drobnjak M., Melamed J., Taneja S., Melzer K., Wieczorek R., Levinson B., Zeleniuch-Jacquotte A., Polsky D., Ferrara J., Perez-Soler R., Cordon-Cardo C., Pagano M., Osman I. Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients. Clin. Cancer Res. 2003, 9:2613-2619.
16. Elinav E., Chajek-Shaul T. Licorice consumption causing severe hypokalemic paralysis. Mayo Clin. Proc. 2003, 78:767-768.
17. Gilligan T., Kantoff P.W. Chemotherapy for prostate cancer. Urology 2002, 60:94-100. (discussion 100).
18. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
19. Hong F., Larrea M.D., Doughty C., Kwiatkowski D.J., Squillace R., Slingerland J.M. mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol. Cell 2008, 30:701-711.
20. Jung J.I., Lim S.S., Choi H.J., Cho H.J., Shin H.K., Kim E.J., Chung W.Y., Park K.K., Park J.H. Isoliquiritigenin induces apoptosis by depolarizing mitochondrial membranes in prostate cancer cells. J. Nutr. Biochem. 2006, 17:689-696.
21. Jung S.K., Lee K.W., Byun S., Kang N.J., Lim S.H., Heo Y.S., Bode A.M., Bowden G.T., Lee H.J., Dong Z. Myricetin suppresses UVB-induced skin cancer by targeting Fyn. Cancer Res. 2008, 68:6021-6029.
22. Khor T.O., Yu S., Barve A., Hao X., Hong J.L., Lin W., Foster B., Huang M.T., Newmark H.L., Kong A.N. Dietary feeding of dibenzoylmethane inhibits prostate cancer in transgenic adenocarcinoma of the mouse prostate model. Cancer Res. 2009, 69:7096-7102.
23. Kiyokawa H., Kineman R.D., Manova-Todorova K.O., Soares V.C., Hoffman E.S., Ono M., Khanam D., Hayday A.C., Frohman L.A., Koff A. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 1996, 85:721-732.
24. Lee Y.S., Kim S.H., Kim J.K., Shin H.K., Kang Y.H., Park J.H., Lim S.S. Rapid identification and preparative isolation of antioxidant components in licorice. J. Sep. Sci. 2010, 33:664-671.
25. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947.
26. Liang J., Zubovitz J., Petrocelli T., Kotchetkov R., Connor M.K., Han K., Lee J.H., Ciarallo S., Catzavelos C., Beniston R., Franssen E., Slingerland J.M. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat. Med. 2002, 8:1153-1160.
27. Lloyd R.V., Erickson L.A., Jin L., Kulig E., Qian X., Cheville J.C., Scheithauer B.W. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am. J. Pathol. 1999, 154:313-323.
28. Macri E., Loda M. Role of p27 in prostate carcinogenesis. Cancer Metastasis Rev. 1998, 17:337-344.
29. Mateos-Aparicio I., Redondo Cuenca A., Villanueva-Suarez M.J., Zapata-Revilla M.A. Soybean, a promising health source. Nutr. Hosp. 2008, 23:305-312.
30. McCall P., Witton C.J., Grimsley S., Nielsen K.V., Edwards J. Is PTEN loss associated with clinical outcome measures in human prostate cancer?. Br. J. Cancer 2008, 99:1296-1301.
31. Moller M.B. P27 in cell cycle control and cancer. Leuk. Lymphoma 2000, 39:19-27.
32. Mumoli N., Cei M. Licorice-induced hypokalemia. Int. J. Cardiol. 2008, 124:e42-e44.
33. Nakayama K., Ishida N., Shirane M., Inomata A., Inoue T., Shishido N., Horii I., Loh D.Y. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996, 85:707-720.
34. Oh W.K. Secondary hormonal therapies in the treatment of prostate cancer. Urology 2002, 60:87-92. discussion 93.
35. Pruitt K., Der C.J. Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett. 2001, 171:1-10.
36. Reuter J., Merfort I., Schempp C.M. Botanicals in dermatology: an evidence-based review. Am. J. Clin. Dermatol. 2010, 11:247-267.
37. Rodier G., Montagnoli A., Di Marcotullio L., Coulombe P., Draetta G.F., Pagano M., Meloche S. p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis. EMBO J. 2001, 20:6672-6682.
38. Rosner M., Siegel N., Valli A., Fuchs C., Hengstschlager M. mTOR phosphorylated at S2448 binds to raptor and rictor. Amino Acids 2010, 38:223-228.
39. Seon M.R., Lim S.S., Choi H.J., Park S.Y., Cho H.J., Kim J.K., Kim J., Kwon D.Y., Park J.H. Isoangustone A present in hexane/ethanol extract of Glycyrrhiza uralensis induces apoptosis in DU145 human prostate cancer cells via the activation of DR4 and intrinsic apoptosis pathway. Mol. Nutr. Food Res. 2010, 54:1329-1339.
40. Sheaff R., Groudine M., Gordon M., Roberts J., Clurman B. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev. 1997, 11:1464.
41. Sheaff R.J., Groudine M., Gordon M., Roberts J.M., Clurman B.E. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev. 1997, 11:1464-1478.
42. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 2012, 62:10-29.
43. Thirugnanam S., Xu L., Ramaswamy K., Gnanasekar M. Glycyrrhizin induces apoptosis in prostate cancer cell lines DU-145 and LNCaP. Oncol. Rep. 2008, 20:1387-1392.
44. Tsihlias J., Kapusta L.R., DeBoer G., Morava-Protzner I., Zbieranowski I., Bhattacharya N., Catzavelos G.C., Klotz L.H., Slingerland J.M. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res. 1998, 58:542-548.
45. Vlach J., Hennecke S., Amati B. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J. 1997, 16:5334-5344.
46. Wang Z.Y., Nixon D.W. Licorice and cancer. Nutr. Cancer 2001, 39:1-11.
47. Wang S., Gao J., Lei Q., Rozengurt N., Pritchard C., Jiao J., Thomas G.V., Li G., Roy-Burman P., Nelson P.S., Liu X., Wu H. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003, 4:209-221.
48. Yang R.M., Naitoh J., Murphy M., Wang H.J., Phillipson J., deKernion J.B., Loda M., Reiter R.E. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J. Urol. 1998, 159:941-945.
49. Yo Y.T., Shieh G.S., Hsu K.F., Wu C.L., Shiau A.L. Licorice and licochalcone-A induce autophagy in LNCaP prostate cancer cells by suppression of Bcl-2 expression and the mTOR pathway. J. Agric. Food Chem. 2009, 57:8266-8273.